Azienda Ospedaliera Ordine Mauriziano di Torino Ospedale Umberto I , SCDU Oncologia Trials

Azienda Ospedaliera Ordine Mauriziano di Torino Ospedale Umberto I , SCDU Oncologia	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Maio, Massimo Di

OINC, NCT04480268: PAXG Out in the Country

Recruiting

175

Europe

PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy

IRCCS San Raffaele

Pancreatic Ductal Adenocarcinoma

01/22

01/26

STAD-1, NCT00526396 / 2006-003995-36: Small Cell Lung Cancer Toxicity Adjusted Dosing Study

Active, not recruiting

160

Europe

cisplatin, etoposide

National Cancer Institute, Naples

Small Cell Lung Cancer

12/23

MILES-4, NCT01656551 / 2012-000164-25: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer

Active, not recruiting

232

Europe

Gemcitabine, Pemetrexed, Cisplatin

National Cancer Institute, Naples

Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB

11/24

PURITY, NCT06037980: CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Recruiting

2/3

300

Europe

Gemcitabine, Nab paclitaxel, Abraxane, Cisplatin, Curative Surgery, Capecitabine

Gruppo Oncologico del Nord-Ovest

Biliary Tract Cancer, Cholangiocarcinoma

12/28

01/29

NCT06341764: Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma

Recruiting

Europe

Durvalumab 1120 mg, Durvalumab 1500 mg, Tremelimumab i.v. at 300 mg, Cisplatin (CDDP) 25 mg/mq i.v, Gemcitabine (GEM) 1000 mg/mq i.v.

National Cancer Institute, Naples

Cholangiocarcinoma

09/25

NCT05266937: Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Active, not recruiting

Europe

Atezolizumab,Paclitaxel, Carboplatin

Consorzio Oncotech

Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation

07/24

BRICKET, NCT06578559: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

Recruiting

Europe

Cetuximab, Encorafenib

Gruppo Oncologico del Nord-Ovest, Merck Sharp & Dohme LLC, Pierre Fabre Laboratories

Colorectal Cancer

08/26

04/27

GDFather-NEO, NCT06059547 / 2022-002816-22: Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

Active, not recruiting

Europe

Nivolumab, Visugromab (CTL-002), Placebo

CatalYm GmbH, CatalYm GmbH

Bladder Cancer, Adult Solid Tumor

08/25

09/26

NCT01593488: Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children

Active, not recruiting

Europe

liposomal cytarabine

National Cancer Institute, Naples, Santobono-Pausilpon Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna

Acute Lymphoblastic Leukemia

12/24

ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting

400

Europe

Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib

Fondazione per la Medicina Personalizzata

Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer

12/24

06/25

CAVE 2, NCT05291156: CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Recruiting

173

Europe

Cetuximab, Erbitux, Avelumab, Bavencio

University of Campania "Luigi Vanvitelli"

Metastatic Colorectal Cancer

07/25

NCT05630937 / 2020-001002-26: Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy

Completed

1/2

Europe, US

NMS-01940153E

Nerviano Medical Sciences

Unresectable Hepatocellular Carcinoma (HCC)

01/24

08/24

TIR-2009-01, NCT01074684: Predictive Factors of Clinical, Laboratory and Imaging Findings Routinely Used in Diagnosing Thyroid Cancer

Completed

N/A

959

Europe

National Cancer Institute, Naples

Thyroid Cancer

12/21

PROPHYBIOTA, NCT05319067: Study of Gut Microbiota Diversity in Children Aged 1-3 Years on Prolonged Antibiotic Prophylaxis for Grade 3 or Higher Vesicoureteral Reflux Compared With 2 Age-matched Control Groups

Recruiting

N/A

150

Europe

Stool sampling

Centre Hospitalier Universitaire de Nīmes

Vesicoureteral Reflux 3

11/26

FAHIC-Lung, NCT06196424: A Study to Investigate the Family History of Cancer in Patients With Non-small Cell Lung Cancer (FAHIC - Lung).

Recruiting

N/A

180

Europe

study questionnaire to investigate family history

Fondazione Policlinico Universitario Campus Bio-Medico, A.O.U. Città della Salute e della Scienza - Molinette Hospital, IRCCS San Raffaele

Non Small Cell Lung Cancer

03/25

11/25

PROFTC-I, NCT03473379: Development and Validation of a Tool for Patient-reported Assessment of Cancer-related Financial Toxicity in Italy

Recruiting

N/A

440

Europe

National Cancer Institute, Naples

Cancer

02/24

07/24

MITO-12, NCT01061619: Pathway to Diagnosis of Ovarian Cancer

Active, not recruiting

N/A

400

Europe

National Cancer Institute, Naples

Ovarian Cancer

11/24

PETRA, NCT02035683: PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy

Active, not recruiting

N/A

220

Europe

PET/CT

National Cancer Institute, Naples

Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB

12/24

ECUN-2, NCT04584320: Identification of Clostridium Butyricum and Clostridium Neonatal in the Digestive Microbiota of Premature Infants Before 34 Weeks and Developing or Not Ulcerative Necrotizing Enterocolitis (NEC) During Hospitalization

Active, not recruiting

N/A

Europe

Stool sample

Centre Hospitalier Universitaire de Nīmes

Necrotizing Enterocolitis

11/24

10/25

REDCLOUD, NCT04232891: Early Detection of Relapses in Stage IV Colorectal Cancer Patients

Recruiting

N/A

141

Europe

liquid biopsy

Fondazione del Piemonte per l'Oncologia

Metastatic Colorectal Cancer

06/21

06/23

Maruzzo, Marco

TIDE-A, NCT04698213: Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

Recruiting

Europe

Axitinib Oral Tablet, Avelumab

Consorzio Oncotech, Clinical Research Technology S.r.l.

Renal Carcinoma Metastatic

09/23

10/24

GDFather-NEO, NCT06059547 / 2022-002816-22: Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

Active, not recruiting

Europe

Nivolumab, Visugromab (CTL-002), Placebo

CatalYm GmbH, CatalYm GmbH

Bladder Cancer, Adult Solid Tumor

08/25

09/26

JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting

256

Europe, Canada, US, RoW

Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics

Locally Advanced or Metastatic Urothelial Carcinoma

01/25

NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Active, not recruiting

Europe, US

UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine

UroGen Pharma Ltd.

Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent

12/25

BDMO, NCT06367491: National Database of Bone Metastases

Recruiting

N/A

800

Europe

Registration in a database

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Bone Metastases

01/30

NCT06235268: Prospective and Multicenter Italian Registry of Locally Advanced-Metastatic Urothelial Carcinoma

Recruiting

N/A

1000

Europe

Active systemic or non-systemic treatment (palliative or observation procedure)

Federation of Italian Cooperative Oncology Groups

Carcinoma, Urothelial

11/25

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Maio, Massimo Di

OINC, NCT04480268: PAXG Out in the Country

Recruiting

175

Europe

PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy

IRCCS San Raffaele

Pancreatic Ductal Adenocarcinoma

01/22

01/26

STAD-1, NCT00526396 / 2006-003995-36: Small Cell Lung Cancer Toxicity Adjusted Dosing Study

Active, not recruiting

160

Europe

cisplatin, etoposide

National Cancer Institute, Naples

Small Cell Lung Cancer

12/23

MILES-4, NCT01656551 / 2012-000164-25: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer

Active, not recruiting

232

Europe

Gemcitabine, Pemetrexed, Cisplatin

National Cancer Institute, Naples

Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB

11/24

Recruiting

2/3

300

Europe

Gemcitabine, Nab paclitaxel, Abraxane, Cisplatin, Curative Surgery, Capecitabine

Gruppo Oncologico del Nord-Ovest

Biliary Tract Cancer, Cholangiocarcinoma

12/28

01/29

NCT06341764: Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma

Recruiting

Europe

Durvalumab 1120 mg, Durvalumab 1500 mg, Tremelimumab i.v. at 300 mg, Cisplatin (CDDP) 25 mg/mq i.v, Gemcitabine (GEM) 1000 mg/mq i.v.

National Cancer Institute, Naples

Cholangiocarcinoma

09/25

NCT05266937: Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Active, not recruiting

Europe

Atezolizumab,Paclitaxel, Carboplatin

Consorzio Oncotech

Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation

07/24

BRICKET, NCT06578559: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

Recruiting

Europe

Cetuximab, Encorafenib

Gruppo Oncologico del Nord-Ovest, Merck Sharp & Dohme LLC, Pierre Fabre Laboratories

Colorectal Cancer

08/26

04/27

GDFather-NEO, NCT06059547 / 2022-002816-22: Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

Active, not recruiting

Europe

Nivolumab, Visugromab (CTL-002), Placebo

CatalYm GmbH, CatalYm GmbH

Bladder Cancer, Adult Solid Tumor

08/25

09/26

NCT01593488: Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children

Active, not recruiting

Europe

liposomal cytarabine

National Cancer Institute, Naples, Santobono-Pausilpon Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna

Acute Lymphoblastic Leukemia

12/24

ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting

400

Europe

Fondazione per la Medicina Personalizzata

Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer

12/24

06/25

CAVE 2, NCT05291156: CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Recruiting

173

Europe

Cetuximab, Erbitux, Avelumab, Bavencio

University of Campania "Luigi Vanvitelli"

Metastatic Colorectal Cancer

07/25

NCT05630937 / 2020-001002-26: Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy

Completed

1/2

Europe, US

NMS-01940153E

Nerviano Medical Sciences

Unresectable Hepatocellular Carcinoma (HCC)

01/24

08/24

TIR-2009-01, NCT01074684: Predictive Factors of Clinical, Laboratory and Imaging Findings Routinely Used in Diagnosing Thyroid Cancer

Completed

N/A

959

Europe

National Cancer Institute, Naples

Thyroid Cancer

12/21

Recruiting

N/A

150

Europe

Stool sampling

Centre Hospitalier Universitaire de Nīmes

Vesicoureteral Reflux 3

11/26

FAHIC-Lung, NCT06196424: A Study to Investigate the Family History of Cancer in Patients With Non-small Cell Lung Cancer (FAHIC - Lung).

Recruiting

N/A

180

Europe

study questionnaire to investigate family history

Fondazione Policlinico Universitario Campus Bio-Medico, A.O.U. Città della Salute e della Scienza - Molinette Hospital, IRCCS San Raffaele

Non Small Cell Lung Cancer

03/25

11/25

PROFTC-I, NCT03473379: Development and Validation of a Tool for Patient-reported Assessment of Cancer-related Financial Toxicity in Italy

Recruiting

N/A

440

Europe

National Cancer Institute, Naples

Cancer

02/24

07/24

MITO-12, NCT01061619: Pathway to Diagnosis of Ovarian Cancer

Active, not recruiting

N/A

400

Europe

National Cancer Institute, Naples

Ovarian Cancer

11/24

PETRA, NCT02035683: PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy

Active, not recruiting

N/A

220

Europe

PET/CT

National Cancer Institute, Naples

Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB

12/24

Active, not recruiting

N/A

Europe

Stool sample

Centre Hospitalier Universitaire de Nīmes

Necrotizing Enterocolitis

11/24

10/25

REDCLOUD, NCT04232891: Early Detection of Relapses in Stage IV Colorectal Cancer Patients

Recruiting

N/A

141

Europe

liquid biopsy

Fondazione del Piemonte per l'Oncologia

Metastatic Colorectal Cancer

06/21

06/23

Maruzzo, Marco

TIDE-A, NCT04698213: Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

Recruiting

Europe

Axitinib Oral Tablet, Avelumab

Consorzio Oncotech, Clinical Research Technology S.r.l.

Renal Carcinoma Metastatic

09/23

10/24

GDFather-NEO, NCT06059547 / 2022-002816-22: Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

Active, not recruiting

Europe

Nivolumab, Visugromab (CTL-002), Placebo

CatalYm GmbH, CatalYm GmbH

Bladder Cancer, Adult Solid Tumor

08/25

09/26

JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting

256

Europe, Canada, US, RoW

Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics

Locally Advanced or Metastatic Urothelial Carcinoma

01/25

NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Active, not recruiting

Europe, US

UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine

UroGen Pharma Ltd.

Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent

12/25

BDMO, NCT06367491: National Database of Bone Metastases

Recruiting

N/A

800

Europe

Registration in a database

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Bone Metastases

01/30

NCT06235268: Prospective and Multicenter Italian Registry of Locally Advanced-Metastatic Urothelial Carcinoma

Recruiting

N/A

1000

Europe

Active systemic or non-systemic treatment (palliative or observation procedure)

Federation of Italian Cooperative Oncology Groups

Carcinoma, Urothelial

11/25



	Diseases Companies Products Productz Mechanisms of Action Sites